查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1476406

勃起功能障碍药物的全球市场：分析 - 按药物类型、给药途径、通路、区域、预测（-2030）

Erectile Dysfunction Drugs Market Forecasts to 2030 - Global Analysis By Drug Type (Viagra, Avanafil and Other Drug Types), Route of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

预计2023年全球勃起功能障碍药物市场规模将达28.3亿美元，预测期内复合年增长率为8.8%，2030年将达51.1亿美元。

勃起功能障碍 (ED) 药物是一种旨在治疗无法获得或维持足以进行性交的勃起的药物。 ED药物的作用是增加阴茎的血流量，使其在性刺激时更容易勃起。常见的 ED 药物包括Sildenafil（威而钢）、他达拉非（犀利士）和伐地那非（艾力达），它们属于一类称为5 型磷酸二酯酶(PDE5) 抑制剂的药物。这些药物通常是口服给药，彻底改变了 ED 治疗，为数百万男性提供了可靠有效的解决方案，以改善他们的性能力和生活品质。

根据《临床流行病学和全球健康杂誌》报道，勃起功能障碍影响全球超过 1.5 亿男性，到 2025 年，这一数字预计将增至 3.22 亿。根据美国国立卫生美国(NIH) 预测，到 2022 年，勃起功能障碍 (ED) 将成为美国非常常见的疾病，每年影响约 3,000 万名男性。

意识和接受度不断提高

勃起功能障碍市场对 ED 药物的认识和接受度不断提高，这意味着 ED 作为一种医疗状况正在被认可和正常化。随着社会态度的演变以及有关性健康的讨论变得更加开放，人们越来越有可能寻求 ED 治疗。这种观念的改变导致人们接受并增加了对 ED 药物作为合法解决方案的需求。此外，教育宣传活动和广告活动在传播对可用治疗方案的认识方面发挥着至关重要的作用，进一步促进了市场成长。

监管障碍

勃起功能障碍药物市场的监管障碍主要是由于严格的核准程序和卫生当局的持续监督。这些障碍包括严格的临床试验以确定安全性和有效性以及遵守标籤和广告法规。此外，对潜在副作用以及与其他药物交互作用的担忧也增加了监管的复杂性。专利保护和智慧财产权方面的争议也会延迟市场进入。克服这些监管障碍需要大量的资源和专业知识，这可能会抑制 ED 药物市场的竞争和创新。

药物开发创新

勃起功能障碍市场的药物开发创新为製药公司和患者提供了充满希望的机会。随着研究人员更了解 ED 的根本原因，例如血管问题、神经病变和荷尔蒙失衡，他们可以针对药物干预的新途径。与威而钢和犀利士等现有药物相比，这项创新可能会带来更有效、更安全的治疗方法，且副作用更少。此外，个人化医疗的突破可能会根据患者的个别特征进行客製化治疗，从而提高疗效和患者满意度。

专利到期

勃起功能障碍药物市场的专利到期威胁是指威而钢、犀利士和艾力达等主要药物即将失去独占权。一旦这些专利到期，学名药可能会进入市场，导致原厂药品牌的竞争加剧并降低价格。这可能会严重影响拥有这些药物专属权的製药公司的收益来源。此外，学名药通常价格较低，这会促使消费者放弃品牌产品。这种竞争格局为企业在日益激烈的竞争中保持市场占有率和盈利带来了挑战。

COVID-19 的影响：

COVID-19 大流行对勃起功能障碍 (ED) 药物市场产生了重大影响。由于行动受到限制，医疗保健重点已转向流行病防范，对 ED 药物的需求出现了波动。第一次封锁导致就诊次数和处方数量减少，但随着限制的放鬆和普及远端医疗的普及，需求增加。由于房屋规定，新婚夫妇和其他亲密活动显着增加，导致与性交相关的活动增加，包括 ED 药物。经济不确定性也影响了消费者在 ED 药物等非必需品上的支出。

威而钢（Sildenafil西地那非）细分市场预计将在预测期内成为最大的细分市场

威而钢（Sildenafil）细分市场在 ED 药物市场的成长可归因于几个因素。威而钢是 ED 治疗领域的先驱，在消费者中建立了强大的品牌影响力和信任。威而钢治疗 ED 的功效已得到证实，并被医生和患者广泛采用。Sildenafil学名药仿製药的上市使其变得更加实惠和容易获得，进一步推动了市场成长。此外，持续的研究和开发工作正在创造创新的配方和交付方法，扩大市场基础。此外，人们对 ED 认识的提高和寻求治疗的非个人化正在促进整个 ED 药物市场的扩张，其中威而钢是主导药物。

预计外用药物领域在预测期内复合年增长率最高

外用药物领域的成长归因于外用製剂提供的便利性和自由裁量权，这吸引了寻求非侵入性治疗选择的消费者。配方技术的进步提高了外用药物的功效和吸收率，提高了其有效性。患者和医疗保健提供者对局部治疗的认识和接受程度不断提高正在推动市场需求。此外，对全身性副作用较少的局部治疗的偏好鼓励了外用药物的采用，从而促进了这一领域的持续扩展。

比最大的地区

由于人们对 ED 认识的不断提高和治疗选择的增多，北美地区的勃起功能障碍药物市场正在显着增长。医疗技术的进步促进了更有效、更安全的 ED 药物的开发，增加了消费者的信任和支持。此外，北美人口老化，压力和久坐生活方式等生活方式因素也导致ED患者增加，增加了治疗需求。该地区强大的医疗基础设施和优惠的报销政策有助于轻鬆获得急诊药物，进一步推动市场成长。

复合年增长率最高的地区：

由于多种因素，亚太地区正在经历显着的快速成长。主要驱动因素包括性健康意识的提高、文明病盛行率的上升以及医疗服务的普及。此外，更公开地讨论性健康的文化转变正在减少耻辱并鼓励个人寻求治疗。此外，创新治疗方案的可用性正在推动市场成长。亚太地区人口众多，医疗基础设施发达，为勃起功能障碍药物市场的进一步扩张提供了重大机会。

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球勃起功能障碍药物市场：依药物类型

  • 威而钢（Sildenafil）
  • 阿伐那非（Stendra/Spedra）
  • 犀利士（他达拉非）
  • Helva（碳酸洛地那非）
  • 艾力达/Staxyn（伐地那非）
  • Mbix（米洛地那非）
  • 维塔罗斯（Alprostadil）
  • Zydena（Udenafil）
  • 其他药物种类

第六章全球勃起功能障碍治疗药物市场：依给药途径

  • 口腔医学
  • 外用药
  • 注射

第七章全球勃起功能障碍治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第八章全球勃起功能障碍治疗药物市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司概况

  • Abbott Laboratories
  • Allergan plc
  • Apricus Biosciences, Inc.
  • Bayer AG
  • Cristalia Produtos Quimicos Farmaceuticos Ltda.
  • Dong-A Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Futura Medical plc
  • Ion Channel Innovations, LLC
  • Johnson & Johnson
  • Meda Pharmaceuticals Inc.
  • Metuchen Pharmaceuticals, LLC
  • Pfizer Inc.
  • Regent Pacific Group Limited
  • Sandoz International GmbH
  • Sinil Pharmaceutical Co., Ltd.
  • SK Chemicals Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS, Inc.
Product Code: SMRC25952

According to Stratistics MRC, the Global Erectile Dysfunction Drugs Market is accounted for $2.83 billion in 2023 and is expected to reach $5.11 billion by 2030 growing at a CAGR of 8.8% during the forecast period. Erectile dysfunction (ED) drugs are medications designed to treat the inability to achieve or maintain an erection sufficient for sexual intercourse. They work by increasing blood flow to the penis, facilitating an erection when sexually stimulated. Common ED drugs include sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra), which belong to a class of medications called phosphodiesterase type 5 (PDE5) inhibitors. These drugs are typically taken orally and have revolutionized the treatment of ED, offering millions of men a reliable and effective solution to enhance their sexual performance and quality of life.

According to the Clinical Epidemiology and Global Health Journal, Erectile Dysfunction affects more than 150 million men globally, and by 2025, that number is predicted to rise to 322 million. According to the National Institutes of Health (NIH), in 2022, erectile dysfunction (ED) is very common condition in U.S. It affects about 30 million men in the U.S. every year.

Market Dynamics:

Driver:

Growing awareness and acceptance

The growing awareness and acceptance of ED drugs in the erectile dysfunction market signifies the increasing recognition and normalization of ED as a medical condition. As societal attitudes evolve and conversations around sexual health become more open, individuals are more likely to seek treatment for ED. This shift in perception leads to greater acceptance of ED drugs as legitimate solutions, boosting their demand. Additionally, education campaigns and advertising efforts play a crucial role in spreading awareness about available treatment options, further fueling market growth.

Restraint:

Regulatory hurdles

Regulatory hurdles in the erectile dysfunction drug market primarily stem from stringent approval processes and ongoing monitoring by health authorities. These hurdles include rigorous clinical trials to establish safety and efficacy, as well as compliance with labeling and advertising regulations. Additionally, concerns over potential side effects and interactions with other medications contribute to the regulatory complexity. Market entry may also be delayed by patent protections and intellectual property disputes. Navigating these regulatory hurdles demands substantial resources and expertise, which can restrain competition and innovation in the ED drug market.

Opportunity:

Innovation in drug development

The innovation in drug development within the erectile dysfunction market presents a promising opportunity for both pharmaceutical companies and patients. With advancements in understanding the underlying causes of ED, such as vascular issues, neurological disorders, and hormonal imbalances, researchers can target novel pathways for drug interventions. This innovation could lead to more effective and safer treatment options, potentially with fewer side effects compared to current medications like Viagra and Cialis. Furthermore, breakthroughs in personalized medicine may enable tailored treatments based on individual patient characteristics, enhancing efficacy and patient satisfaction.

Threat:

Patent expiry

The patent expiry threat in the Erectile Dysfunction drugs market refers to the looming loss of exclusivity for major medications like Viagra, Cialis, and Levitra. As these patents expire, generic versions can enter the market, leading to intense competition and price erosion for the original brands. This could significantly impact revenue streams for pharmaceutical companies that have held exclusive rights to these drugs. Moreover, generic alternatives often come at lower prices, enticing consumers away from branded products. This scenario poses a challenge for companies to maintain market share and profitability in the face of increased competition.

Covid-19 Impact:

The COVID-19 pandemic had a significant impact on the erectile dysfunction (ED) drug market. With restrictions on movement and healthcare priorities shifting towards managing the pandemic, the demand for ED drugs saw fluctuations. While initial lockdowns led to a decrease in doctor visits and prescriptions, there was a subsequent rise in demand as restrictions eased and telemedicine became more prevalent. Due to house restrictions, there was a substantial growth of intimate activities among newlywed couples and others, which consequently led to growth of several things related to intercourse including ED drugs. Economic uncertainties also influenced consumer spending on non-essential medications like ED drugs.

The viagra (sildenafil citrate) segment is expected to be the largest during the forecast period

The growth of the Viagra (Sildenafil Citrate) segment in the ED drug market can be attributed to several factors. Viagra was one of the pioneering drugs in ED treatment, establishing a strong brand presence and trust among consumers. Its efficacy in treating ED is well-established, leading to widespread adoption by physicians and patients alike. The availability of generic versions of Sildenafil Citrate has increased affordability and accessibility, further fueling market growth. Moreover, continuous research and development efforts have resulted in innovative formulations and delivery methods, expanding the market reach. Furthermore, increasing awareness about ED and the destigmatization of seeking treatment have contributed to the overall expansion of the ED drug market, with Viagra leading the charge.

The topical medications segment is expected to have the highest CAGR during the forecast period

The growth in the topical medication segment can be attributed to the convenience and discretion offered by topical formulations, appealing to consumers seeking non-invasive treatment options. Advancements in formulation technology have improved the efficacy and absorption rates of topical medications, enhancing their effectiveness. The growing awareness and acceptance of topical treatments among both patients and healthcare providers have fuelled market demand. Additionally, the preference for localized treatment with fewer systemic side effects has bolstered the adoption of topical medications, contributing to the segment's sustained expansion.

Region with largest share:

The North American region has experienced significant growth in the erectile dysfunction drug market due to increasing awareness about ED and its growing treatment options. Advancements in medical technology have led to the development of more effective and safer ED drugs, boosting consumer confidence and uptake. Additionally, the aging population in North America, coupled with lifestyle factors such as stress and sedentary habits, has contributed to the rise in ED cases, thus driving the demand for treatment. Robust healthcare infrastructure and favourable reimbursement policies in the region have facilitated access to ED drugs, further fuelling market growth.

Region with highest CAGR:

The Asia-Pacific region has witnessed a notable surge due to several factors. Increasing awareness about sexual health, the rising incidence of lifestyle-related disorders, and expanding access to healthcare services are key drivers. Furthermore, cultural shifts towards more open discussions about sexual health have reduced stigma, encouraging individuals to seek treatment. Furthermore, the availability of innovative treatment options has fuelled market growth. With a large population base and improving healthcare infrastructure, the Asia-Pacific region presents significant opportunities for further expansion in the erectile dysfunction drug market.

Key players in the market

Some of the key players in Erectile Dysfunction Drugs market include Abbott Laboratories, Allergan plc, Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co., Ltd., Eli Lilly and Company, Endo International plc, Futura Medical plc, Ion Channel Innovations, LLC, Johnson & Johnson, Meda Pharmaceuticals Inc., Metuchen Pharmaceuticals, LLC, Pfizer Inc., Regent Pacific Group Limited, Sandoz International GmbH, Sinil Pharmaceutical Co., Ltd., SK Chemicals Co., Ltd., Teva Pharmaceutical Industries Ltd. and VIVUS, Inc.

Key Developments:

In March 2024, Johnson & Johnson's JNJ wholly-owned subsidiary, Johnson & Johnson MedTech, recently announced its partnership with Nvidia to accelerate secure, real-time analysis of surgical data using artificial intelligence (AI). The two businesses collaborated to enable more global availability of AI algorithms and real-time analytical access. Their goal is to have an impact on surgical decision-making, teamwork, and education in all linked operating rooms (ORs).

In January 2024, Glenmark said it has partnered with Pfizer to launch abrocitinib in India used for treatment of moderate-to-severe atopic dermatitis (AD). Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO. Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO).

Drug Types Covered:

  • Viagra (Sildenafil Citrate)
  • Avanafil (Stendra/Spedra)
  • Cialis (Tadalafil)
  • Helleva (Lodenafil Carbonate)
  • Levitra/Staxyn (Vardenafil)
  • Mvix (Mirodenafil)
  • Vitaros (Alprostadil)
  • Zydena (Udenafil)
  • Other Drug Types

Route of Administrations Covered:

  • Oral Medications
  • Topical Medications
  • Injections

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Erectile Dysfunction Drugs Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Viagra (Sildenafil Citrate)
  • 5.3 Avanafil (Stendra/Spedra)
  • 5.4 Cialis (Tadalafil)
  • 5.5 Helleva (Lodenafil Carbonate)
  • 5.6 Levitra/Staxyn (Vardenafil)
  • 5.7 Mvix (Mirodenafil)
  • 5.8 Vitaros (Alprostadil)
  • 5.9 Zydena (Udenafil)
  • 5.10 Other Drug Types

6 Global Erectile Dysfunction Drugs Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral Medications
  • 6.3 Topical Medications
  • 6.4 Injections

7 Global Erectile Dysfunction Drugs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Online Pharmacies
  • 7.4 Retail Pharmacies

8 Global Erectile Dysfunction Drugs Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott Laboratories
  • 10.2 Allergan plc
  • 10.3 Apricus Biosciences, Inc.
  • 10.4 Bayer AG
  • 10.5 Cristalia Produtos Quimicos Farmaceuticos Ltda.
  • 10.6 Dong-A Pharmaceutical Co., Ltd.
  • 10.7 Eli Lilly and Company
  • 10.8 Endo International plc
  • 10.9 Futura Medical plc
  • 10.10 Ion Channel Innovations, LLC
  • 10.11 Johnson & Johnson
  • 10.12 Meda Pharmaceuticals Inc.
  • 10.13 Metuchen Pharmaceuticals, LLC
  • 10.14 Pfizer Inc.
  • 10.15 Regent Pacific Group Limited
  • 10.16 Sandoz International GmbH
  • 10.17 Sinil Pharmaceutical Co., Ltd.
  • 10.18 SK Chemicals Co., Ltd.
  • 10.19 Teva Pharmaceutical Industries Ltd.
  • 10.20 VIVUS, Inc.

List of Tables

  • Table 1 Global Erectile Dysfunction Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
  • Table 4 Global Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
  • Table 5 Global Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
  • Table 6 Global Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
  • Table 7 Global Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
  • Table 8 Global Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
  • Table 9 Global Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
  • Table 10 Global Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
  • Table 11 Global Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 12 Global Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 13 Global Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
  • Table 14 Global Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
  • Table 15 Global Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
  • Table 16 Global Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 17 Global Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 18 Global Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 19 Global Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 20 North America Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 22 North America Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
  • Table 23 North America Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
  • Table 24 North America Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
  • Table 25 North America Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
  • Table 26 North America Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
  • Table 27 North America Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
  • Table 28 North America Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
  • Table 29 North America Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
  • Table 30 North America Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 31 North America Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 32 North America Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
  • Table 33 North America Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
  • Table 34 North America Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
  • Table 35 North America Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 36 North America Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 37 North America Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 38 North America Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 39 Europe Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 41 Europe Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
  • Table 42 Europe Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
  • Table 43 Europe Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
  • Table 44 Europe Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
  • Table 45 Europe Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
  • Table 46 Europe Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
  • Table 47 Europe Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
  • Table 48 Europe Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
  • Table 49 Europe Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 50 Europe Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 51 Europe Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
  • Table 52 Europe Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
  • Table 53 Europe Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
  • Table 54 Europe Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 55 Europe Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 56 Europe Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 57 Europe Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 58 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 60 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
  • Table 61 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
  • Table 62 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
  • Table 63 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
  • Table 64 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
  • Table 65 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
  • Table 66 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
  • Table 67 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
  • Table 68 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 69 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 70 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
  • Table 71 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
  • Table 72 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
  • Table 73 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 74 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 75 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 76 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 77 South America Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 79 South America Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
  • Table 80 South America Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
  • Table 81 South America Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
  • Table 82 South America Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
  • Table 83 South America Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
  • Table 84 South America Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
  • Table 85 South America Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
  • Table 86 South America Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
  • Table 87 South America Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 88 South America Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 89 South America Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
  • Table 90 South America Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
  • Table 91 South America Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
  • Table 92 South America Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 93 South America Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 94 South America Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 95 South America Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 96 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 98 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
  • Table 99 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
  • Table 100 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
  • Table 101 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
  • Table 102 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
  • Table 103 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
  • Table 104 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
  • Table 105 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
  • Table 106 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 107 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 108 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
  • Table 109 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
  • Table 110 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
  • Table 111 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 112 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 113 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 114 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)